Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1-Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the German-Austrian AML Study Group (AMLSG)
2018 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1-Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the German-Austrian AML Study Group (AMLSG)
Kapp-Schwoerer, S.; Weber, D.; Corbacioglu, A.; Gaidzik, V. I.; Paschka, P.; Krönke, J. & Teleanu, M.-V. et al. (2018)
Blood, 132(Supplement 1) pp. 991-991. DOI: https://doi.org/10.1182/blood-2018-99-114648
Documents & Media
Details
- Authors
- Kapp-Schwoerer, Silke; Weber, Daniela; Corbacioglu, Andrea; Gaidzik, Verena I.; Paschka, Peter; Krönke, Jan; Teleanu, Maria-Veronica; Theis, Frauke; Rücker, Frank G.; Göhring, Gudrun; Schlegelberger, Brigitte; Fiedler, Walter; Kindler, Thomas; Schroeder, Thomas Michael; Mayer, Karin; Lübbert, Michael; Wattad, Mohammed Amen; Götze, Katharina S.; Horst, Heinz A.; Koller, Elisabeth; Wulf, Gerald ; Schleicher, Jan; Bentz, Martin; Krauter, Jürgen; Krzykalla, Julia; Benner, Axel; Schlenk, Richard F.; Thol, Felicitas; Heuser, Michael; Ganser, Arnold; Döhner, Hartmut; Döhner, Konstanze
- Issue Date
- 2018
- Journal
- Blood
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
